ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
447 Views
Medlive Technology IPO: Forecasts and Valuation
Based on our forecasts, Medlive’s indicative IPO pricing is still attractive even if we assume a discount rate of 12.0% and a 0% terminal growth...
546 Views
Medlive Technology IPO: Valuation Insights
Our base-case DCF valuation is HK$31.80 per share. Overall, we would participate in the IPO due to an attractive price range and strong blue-chip...
754 Views
Medlive Tech IPO (Part II): Further Room for Margin Expansion with Expanding Scale
Medlive already generates healthy margins and we expect the company's margins to continue to expand with increase in the number of healthcare...
358 Views
Medlive (医脉通) IPO: Candidate for Multi-Bagger
We look at the deal term of Medlive IPO and provide an update for the book building. We think there's substantial upside from both its existing...
532 Views